Technical CommentsCancer

Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

See allHide authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaal2439
DOI: 10.1126/scitranslmed.aal2439

Abstract

Although the combination of decitabine and platinum drugs may be promising for therapy of renal cell carcinoma, the role of OCT2 needs further investigations.

View Full Text